Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo's Rx Business Looks Ready To Sell, Says Hedge Fund Investor

Executive Summary

Starboard Value states says Perrigo "severely mismanaged" its entry into branded consumer health through the acquisition of a German firm and showed "misguided confidence" in encouraging shareholders to reject Mylan's tender.


Related Content

Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?
Perrigo Makes Its Rx Generics Business Look Right At Home
Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope
Perrigo Deal Makes Extraction-Resistant PSE A Two-Player Competition
Perrigo Hopes Esomeprazole Helps Make Private Label OTCs A Bright Spot
Perrigo Shareholder Lawsuits Claim Joining Mylan Was A Better Idea
Perrigo Out From Under VMS Weight As IVC Lifts Private Label Profile
Culture Shock In Europe For Perrigo With Branded Consumer Business


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts